Skip to main content
. Author manuscript; available in PMC: 2021 May 24.
Published in final edited form as: Cell Syst. 2020 Mar 18;10(3):223–239.e9. doi: 10.1016/j.cels.2020.02.008

Fig.4. SCFA reduce innate immunity of the UC gut MPS and beneficially affect hepatic metabolism during interaction.

Fig.4

(A,C) Volcano plots of DEG in the gut MPS (A) and the liver MPS (C) in presence or absence of SCFA. (B,D) Network of enriched (magenta) and downregulated (blue) pathways based on KEGG in gut MPS (B) or liver MPS (D). (E) Clustered heatmap of multiplexed cytokines/chemokines present in circulating common media at day 2 and 4 during gut-liver MPS interaction +/- SCFA. For concrete concentrations of measured proteins and their importance consult Fig.S4. (F) Significantly enriched metabolic pathways based on quantification of metabolites found in the common medium at day 4 of gut-liver-SCFA interactions. (G,H) Integration of significantly upregulated genes in the UC gut MPS (G) or liver MPS (H) during interaction with SCFA and enriched metabolites found in the common medium at day 4. Pathway impact score is shown on the x-axis and statistical significance on the y-axis. All data represents 3 biological replicates.